NAD+ and Cellular Aging: The Sirtuin Pathway Explained

NAD+ has become a flagship molecule of the modern longevity literature. The reason is the sirtuin pathway: a set of enzymes that depend on NAD+ as a cofactor and that sit at the center of several cellular processes that change with age. Understanding the sirtuin pathway is the cleanest way to understand both what NAD+ supplementation actually does and what the limits of those effects are.

This article explains the sirtuin pathway in clinically useful terms, walks through what raising NAD+ does at the cellular level, distinguishes what the data supports from what is hypothesis, and describes what prescribed NAD+ realistically addresses for patients who are interested in longevity rather than performance.

What sirtuins are

Sirtuins are a family of seven enzymes in mammals, designated SIRT1 through SIRT7. They are deacetylases — enzymes that remove acetyl groups from other proteins — but they are unusual deacetylases for one specific reason: they require NAD+ as a substrate to perform the reaction. The reaction is:

NAD+ + acetylated protein → nicotinamide + O-acetyl-ADP-ribose + deacetylated protein

The biological consequence is that sirtuins act as a bridge between metabolic state (reflected in NAD+ availability) and gene-expression and protein-activity state (reflected in acetylation patterns). When NAD+ is high, sirtuins are active and deacetylation proceeds. When NAD+ is low, sirtuins are limited.

The seven sirtuins are not interchangeable. They live in different cellular compartments and act on different substrates:

• SIRT1 and SIRT2. Predominantly nuclear and cytoplasmic. SIRT1 deacetylates a long list of transcription factors and regulatory proteins, including PGC-1-alpha (a master regulator of mitochondrial biogenesis), p53 (a tumor-suppressor and stress-response protein), and FOXO family members (involved in metabolic and longevity regulation).
• SIRT3, SIRT4, and SIRT5. Mitochondrial. They regulate mitochondrial protein acetylation, oxidative phosphorylation efficiency, and metabolic flexibility.
• SIRT6 and SIRT7. Predominantly nuclear, with roles in DNA repair, telomere maintenance, and ribosomal RNA transcription.

The collective function of the family covers a meaningful share of the cellular processes that decline with age: mitochondrial efficiency, DNA repair capacity, inflammatory regulation, and metabolic flexibility.

Why NAD+ availability matters

The cellular-aging connection runs through a single observation: NAD+ levels decline with age. The decline has been measured across multiple tissues and species, and the magnitude is meaningful — typical estimates put adult tissue NAD+ at perhaps half the level of young-adult tissue across several decades of aging.

The cause of the decline is not single. Contributors include:

1. Increased NAD+ consumption by CD38. CD38 is a NAD+-consuming enzyme whose activity rises with age, particularly with the chronic low-grade inflammation typical of aging tissue.
2. Reduced NAD+ biosynthesis. Several enzymes in the salvage and de novo synthesis pathways for NAD+ become less efficient with age.
3. PARP activation in response to DNA damage. PARP enzymes consume NAD+ during DNA repair, and the cumulative DNA-damage burden of aging increases their activation.
4. Sirtuin consumption itself. Sirtuin reactions consume NAD+, so the same pathway that depends on NAD+ also depletes it. This creates a feedback loop where NAD+ decline compromises the very processes that would otherwise maintain cellular function.

The consequence is that as NAD+ falls, sirtuin activity falls, and the downstream processes — mitochondrial biogenesis, DNA repair, inflammation regulation, metabolic flexibility — all run at reduced capacity. This is a meaningful component of the cellular-aging picture, though it is not the entire picture.

What raising NAD+ does at the cellular level

Restoring NAD+ — whether through parenteral administration of NAD+ itself or through oral precursors like NMN or NR — has several documented effects in human and animal studies:

Improved mitochondrial function. Cellular respiration assays in tissue from supplemented subjects show improved efficiency. The mechanism is plausibly through restored SIRT3 activity (which directly regulates mitochondrial protein acetylation and metabolic flexibility) and through SIRT1-mediated PGC-1-alpha activation (which drives mitochondrial biogenesis).

Enhanced DNA repair capacity. PARP-mediated repair benefits from adequate NAD+ availability; SIRT6 also contributes to repair processes. Restoring NAD+ supports these pathways.

Reduced inflammatory tone. SIRT1 deacetylates and inactivates NF-kB, a master regulator of inflammatory gene expression. With more NAD+, more SIRT1 activity, less NF-kB acetylation, less inflammatory transcription. The clinical consequence in supplemented populations has been measurable reductions in inflammatory biomarkers in some studies.

Improved metabolic flexibility. The capacity to switch between glucose and fatty-acid oxidation as fuel sources declines with age and is in part regulated by mitochondrial sirtuin activity. Restoring NAD+ improves this flexibility in animal models and some human studies.

Subjective changes in fatigue, energy, and sleep. These outcomes are reported consistently, though they are subjective by construction. They cannot stand alone, but they are consistent with the objective biomarker changes.

What raising NAD+ does not clearly do, despite some marketing:

• Reverse aging in any global sense
• Extend human lifespan (this has not been shown in humans; the animal data is mixed and the translation to humans is unproven)
• Restore lost function (cognitive, physical, or otherwise) where the underlying tissue damage is structural

The honest characterization is that NAD+ supplementation addresses one component of the aging process — the metabolic and sirtuin-dependent component — rather than the whole of it.

What the human data shows

The human evidence base for NAD+ and NAD+ precursors has grown meaningfully in the last several years. The endpoints with the strongest support:

• Restoration of NAD+ levels. Both parenteral NAD+ and oral precursors raise blood and tissue NAD+. This is the foundational pharmacokinetic finding and is well-established.
• Improvement in mitochondrial respiration markers. Multiple studies in older adults and in athletic populations have shown improvement.
• Reduction in some inflammatory markers. CRP, IL-6, and related markers have shown reductions in supplemented populations, particularly older adults.
• Subjective improvements in fatigue and energy. Patient-reported outcomes have been consistent across studies.

Endpoints with weaker or more variable support:

• Cognitive function in aging populations. Some signal, but the data is heterogeneous and the effect sizes are modest where they are present.
• Cardiovascular endpoints. Some animal and short-term human data; long-term outcome data is limited.
• Hard aging endpoints (lifespan, healthspan). Not established in humans. The animal data is informative but not directly translatable.

The summary version: NAD+ has good evidence for what it does at the cellular and biomarker level, modest evidence for subjective outcomes, and not-yet-established evidence for the long-term aging endpoints that the marketing sometimes claims.

Parenteral NAD+ versus oral precursors

Two different supplementation approaches raise NAD+:

Parenteral NAD+. Direct administration of NAD+ itself, via subcutaneous, intramuscular, or intravenous routes. Pharmacokinetic profile: rapid availability, NAD+ is the active substrate already, but the molecule is large and tissue distribution depends on delivery route.

Oral NMN or NR. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are orally bioavailable precursors that the body converts to NAD+ through the salvage pathway. They have substantial human data and raise blood and tissue NAD+ measurably.

The choice between them depends on:

• Clinical goal. For aggressive elevation in a focused protocol, parenteral is more direct. For long-term maintenance, oral precursors are practical.
• Cost and convenience. Oral precursors avoid injection. Parenteral is more expensive per dose but is sometimes preferred for the protocol shape.
• Route preference. Patients who do not want injections favor oral; patients who want maximum NAD+ elevation favor parenteral.

Both approaches have legitimate use cases. They are not directly interchangeable, but they are not in opposition — some protocols use oral precursors as a maintenance strategy with periodic parenteral courses.

Regulatory status

NAD+ as a parenteral therapy is not FDA approved as a finished drug product for an aging or longevity indication. Parenteral NAD+ is typically prepared by compounding pharmacies and prescribed off-label by licensed prescribers. The compounding context is regulated; the off-label prescribing is legal where the prescriber has a legitimate clinical basis.

Oral NMN and NR have a different regulatory situation. They are sold as dietary supplements under FDA's supplement framework, which is not a drug approval but is a regulated category.

The marketing landscape includes claims that NAD+ is "FDA approved" for anti-aging or longevity. These claims are not consistent with the regulatory state. A responsible prescriber will not represent NAD+ as approved for longevity, and a responsible patient should be skeptical of marketing that does.

What prescribed NAD+ realistically addresses

For patients on a TelePeptide longevity-oriented NAD+ protocol, the realistic expectations are:

Subjective improvements within a few weeks. Fatigue, energy, sleep quality, and recovery from cognitive or physical exertion typically show changes in the two-to-six-week window.

Biomarker improvements over months. Mitochondrial markers, inflammatory markers, and where measured, glycemic markers tend to follow on a slower timeline.

Long-run support for cellular processes affected by sirtuin function. This is the underlying biology of the protocol. The patient does not feel a sirtuin reaction directly, but the cumulative effect on cellular function over years is the part of the story that justifies the protocol's longevity framing.

What it does not realistically deliver:

• Anti-aging in a cosmetic or rejuvenation sense
• Reversal of established age-related disease
• Lifespan extension that is measurable in any patient's individual horizon

The patients who get the most out of NAD+ are typically those who treat it as one component of a broader longevity framework — alongside sleep, nutrition, exercise, metabolic health management — rather than as a singular intervention.

Bottom line

The sirtuin pathway is the cleanest mechanistic explanation for why NAD+ matters in cellular aging. Sirtuins regulate a meaningful share of the processes that decline with age and they require NAD+ to function. NAD+ levels fall with age, sirtuin activity falls with NAD+, and supplementation addresses one node of that cascade.

The honest characterization of prescribed NAD+ as a longevity intervention is that it addresses one component of cellular aging, with biomarker-level and subjective evidence to support it, without delivering the dramatic outcomes that some marketing implies. For patients who want to engage with the cellular-aging biology in a measured way, the prescribed model — with eligibility review, structured dosing, and tracked outcomes — is the right channel.